Yuhan Corporation’s licensed-out non-alcoholic steatohepatitis drug to start phase 1 clinical trial in Europe
Expected to receive 10 million USD as a milestone payment Yuhan Corporation (000100. KS) announced on the 17th of November that the new drug candidate (YH25724) for the treatment of ...
Read More
Read More
Yuhan Corporation to invest 1.6 billion Won (1.34 million USD) in Yuhan USA U.S. Open Innovation Investment Continues
Yuhan USA strengthens its role as a 'venture capital'. They purchased 750,000 shares of Processa Pharmaceuticals this year. Yuhan Corporation is spurring overseas open innovation expansion and strengthening its global ...
Read More
Read More
Processa Pharmaceuticals’ PCS12852, originally developed by Yuhan Corp, cleared by FDA to Proceed with Ph2a Trial for Gastroparesis
Processa Pharmaceuticals announced that they have been cleared by the FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis. PCS12852 is ...
Read More
Read More
[Job Opening] Associate, Business Operations – San Diego office
Job description Responsibilities: Provide administrative support to include arranging travel plans and meetings; interact and liaise with members of the functional team, management and external clientsPerform office duties that include ...
Read More
Read More
Yuhan Corporation – Introduction Video
Learn more about our parent company “Yuhan Corporation by watching this video ...
Read More
Read More
Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million
Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of ...
Read More
Read More
[Job Opening] Business Development Manager – San Diego office
Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an outpost of Yuhan’s globalization strategy, ...
Read More
Read More
Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody
Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for ...
Read More
Read More
Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation
Yuhan Corporation has in-licensed GI Innovation's allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation ...
Read More
Read More
Yuhan Corporation to recoup KRW 200 billion investment in five years
Yuhan Corporation's global R&D and open innovation strategy - in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the ...
Read More
Read More